fenoterol ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
bronchodilators, phenethylamine derivatives 1155 13392-18-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fenoterol
  • phenoterol
  • fenoterol hydrobromide
  • fenoterol hydrochloride
  • fenoterol HCl
A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.
  • Molecular weight: 303.36
  • Formula: C17H21NO4
  • CLOGP: 0.98
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 5
  • TPSA: 92.95
  • ALOGS: -3.27
  • ROTB: 6

Drug dosage:

DoseUnitRoute
0.60 mg Inhal.aerosol
0.60 mg Inhal.powder
4 mg Inhal.solution
10 mg O
10 mg R

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.08 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 2 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 29 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.53 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.87 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.16 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1965 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Congenital coronary artery malformation 68.43 28.62 10 1680 138 63487194
Polyneuropathy 51.53 28.62 18 1672 14571 63472761
Pancreatic steatosis 49.19 28.62 10 1680 1006 63486326
Acute respiratory failure 48.94 28.62 22 1668 34463 63452869
Asthmatic crisis 48.80 28.62 11 1679 1802 63485530
Polyhydramnios 46.34 28.62 11 1679 2260 63485072
Arterial thrombosis 45.69 28.62 10 1680 1433 63485899
Sinus arrhythmia 45.48 28.62 10 1680 1463 63485869
Cervical incompetence 41.54 28.62 8 1682 609 63486723
Erysipelas 36.77 28.62 12 1678 7893 63479439
Delirium 32.75 28.62 19 1671 50522 63436810
Hypercapnia 32.54 28.62 10 1680 5421 63481911
Asthma 30.47 28.62 26 1664 127535 63359797
Renal cyst 29.92 28.62 11 1679 10291 63477041
Systemic infection 29.71 28.62 9 1681 4651 63482681

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood phosphorus increased 90.02 28.23 31 2873 7690 34946337
Appendicolith 82.98 28.23 30 2874 8571 34945456
Appendicitis 67.20 28.23 30 2874 14777 34939250
Myasthenia gravis 62.45 28.23 23 2881 6917 34947110
Cardiogenic shock 61.30 28.23 34 2870 26584 34927443
Ventricular fibrillation 57.50 28.23 31 2873 22923 34931104
Stress 54.55 28.23 33 2871 30314 34923713
Dry mouth 49.62 28.23 31 2873 30134 34923893
Chronic obstructive pulmonary disease 48.98 28.23 37 2867 48881 34905146
Blood uric acid increased 48.50 28.23 21 2883 9603 34944424
Abdominal distension 43.15 28.23 37 2867 58455 34895572
Congenital cystic lung 40.19 28.23 8 2896 226 34953801
Bacterial infection 37.09 28.23 21 2883 17042 34936985
General physical health deterioration 36.67 28.23 49 2855 128220 34825807
Ascites 35.43 28.23 30 2874 46541 34907486
Xanthelasma 33.45 28.23 6 2898 95 34953932
Neonatal respiratory failure 31.07 28.23 7 2897 361 34953666
Blood cholesterol increased 30.99 28.23 20 2884 20523 34933504
Hyperphosphataemia 30.19 28.23 12 2892 4425 34949602
Hydrops foetalis 29.76 28.23 8 2896 859 34953168
Tobacco abuse 29.74 28.23 7 2897 439 34953588
Condition aggravated 29.26 28.23 55 2849 192141 34761886

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 95.87 23.91 30 4264 8521 79731573
Blood phosphorus increased 94.25 23.91 31 4263 10316 79729778
Appendicitis 69.86 23.91 30 4264 20764 79719330
Chronic obstructive pulmonary disease 64.72 23.91 46 4248 85373 79654721
Congenital coronary artery malformation 63.80 23.91 10 4284 106 79739988
Ventricular fibrillation 63.39 23.91 32 4262 31894 79708200
Myasthenia gravis 63.07 23.91 23 4271 10376 79729718
Cardiogenic shock 60.59 23.91 34 4260 41880 79698214
General physical health deterioration 55.42 23.91 71 4223 275167 79464927
Acute respiratory failure 49.60 23.91 34 4260 59507 79680587
Blood uric acid increased 47.26 23.91 20 4274 13340 79726754
Pancreatic steatosis 40.96 23.91 10 4284 1135 79738959
Stress 40.80 23.91 34 4260 79578 79660516
Ascites 40.24 23.91 33 4261 75529 79664565
Asthmatic crisis 39.98 23.91 11 4283 1995 79738099
Abdominal distension 39.61 23.91 40 4254 119610 79620484
Polyhydramnios 36.92 23.91 10 4284 1710 79738384
Sinus arrhythmia 34.90 23.91 10 4284 2100 79737994
Dry mouth 33.94 23.91 32 4262 87987 79652107
Asthma 33.88 23.91 39 4255 135056 79605038
Dyspnoea 33.07 23.91 111 4183 856914 78883180
Xanthelasma 32.89 23.91 6 4288 165 79739929
Arterial thrombosis 32.56 23.91 10 4284 2664 79737430
Cervical incompetence 31.59 23.91 7 4287 520 79739574
Hyperphosphataemia 31.01 23.91 12 4282 6364 79733730
Electrocardiogram abnormal 30.95 23.91 16 4278 16721 79723373
Polyneuropathy 30.63 23.91 18 4276 24133 79715961
Systemic infection 29.26 23.91 13 4281 9739 79730355
Somnolence 28.20 23.91 48 4246 238933 79501161
Infective exacerbation of chronic obstructive airways disease 28.01 23.91 9 4285 2775 79737319
Erysipelas 27.93 23.91 13 4281 10837 79729257
Tobacco abuse 27.09 23.91 7 4287 999 79739095
Analgesic therapy 27.07 23.91 7 4287 1002 79739092
Sleep disorder therapy 26.97 23.91 7 4287 1017 79739077
Bacterial infection 26.36 23.91 18 4276 31262 79708832
Drug therapy 25.86 23.91 7 4287 1194 79738900
Multiple organ dysfunction syndrome 25.68 23.91 32 4262 120214 79619880
Hyponatraemia 25.44 23.91 39 4255 177809 79562285
Traumatic haemorrhage 25.14 23.91 7 4287 1326 79738768
Iron deficiency 25.08 23.91 12 4282 10642 79729452
Condition aggravated 23.93 23.91 70 4224 501054 79239040

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G02CA03 GENITO URINARY SYSTEM AND SEX HORMONES
OTHER GYNECOLOGICALS
OTHER GYNECOLOGICALS
Sympathomimetics, labour repressants
ATC R03AC04 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Selective beta-2-adrenoreceptor agonists
ATC R03AL01 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC R03CC04 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS FOR SYSTEMIC USE
Selective beta-2-adrenoreceptor agonists
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058666 Adrenergic beta-2 Receptor Agonists
MeSH PA D000318 Adrenergic beta-Agonists
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D012102 Reproductive Control Agents
MeSH PA D019141 Respiratory System Agents
MeSH PA D013566 Sympathomimetics
MeSH PA D015149 Tocolytic Agents
CHEBI has role CHEBI:35522 beta-adrenergic agonists
CHEBI has role CHEBI:35523 bronchodilator
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:66993 tocolytic drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

None




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.48 acidic
pKa2 11.02 acidic
pKa3 11.67 acidic
pKa4 12.2 acidic
pKa5 8.03 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR AGONIST EC50 6.90 WOMBAT-PK IUPHAR
Beta-2 adrenergic receptor GPCR IC50 7.22 CHEMBL

External reference:

IDSource
4025246 VUID
N0000171778 NUI
D01428 KEGG_DRUG
4025246 VANDF
C0015840 UMLSCUI
CHEBI:149226 CHEBI
CHEMBL32800 ChEMBL_ID
DB01288 DRUGBANK_ID
D005280 MESH_DESCRIPTOR_UI
3343 PUBCHEM_CID
557 IUPHAR_LIGAND_ID
3073 INN_ID
36369-23-0 SECONDARY_CAS_RN
1944-10-1 SECONDARY_CAS_RN
22M9P70OQ9 UNII
203124 RXNORM
003460 NDDF
003461 NDDF
349924004 SNOMEDCT_US
395976006 SNOMEDCT_US
396053003 SNOMEDCT_US
CHEMBL537445 ChEMBL_ID
130156-24-0 SECONDARY_CAS_RN

Pharmaceutical products:

None